COVID-19 vaccine safety and efficacy in systemic lupus erythematosus: A systematic review.

Systemic lupus erythematosus (SLE) is a kind of autoimmune disease in rheumatic which can range in severity and organ involvement. Immune dysregulation is an SLE feature that is exacerbated by immunosuppressive drugs. In SLE, most live vaccinations are contraindicated, and the immune response underperforms because of immunosuppressive medications. Therefore, this paper aims to examine COVID-19 vaccine safety and effectiveness in Systemic Lupus Erythematosus. We systematically searched Cochrane, Pubmed, and Scopus for peer-reviewed studies examining the COVID-19 vaccine safety and efficacy in Systemic Lupus Erythematosus. The research featured in this review was conducted between 2000 and 2022; the article's entire text is available upon request, and the patient's age is over 18 years. Using the Cochrane Risk of Bias Assessment Tool, three reviewers independently retrieved data on pertinent clinical outcomes, studies, and patient characteristics. The evidence's reliability was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation system. COVID-19 vaccinations are safe in SLE, whereas mRNA vaccines cause more significant local responses. The adverse effects were mild local soreness, weariness, and a headache. The chances of many lupus flares are slim. COVID-19 immunization is less efficient than in the whole population, especially in individuals with immunosuppressive medications or inactivated vaccines. [ABSTRACT FROM AUTHOR]